Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Full coverage· Economy· Updated

Teva R&D Chief Arik Yoz Departs One Week After Strategy Unveiling

Teva Pharmaceuticals announced that Dr. Arik Yoz, its Senior Vice President for Global R&D and Chief Medical Officer, is leaving the company. His departure comes a week after Teva presented its innovative medicines strategy and revenue goals for 2030.

2 newsrooms · 1 language · since

Sign in to baba News

Sign in to save this article and find it on your phone.

or use an email code

What happened

  1. 01Teva's Senior VP of R&D, Dr. Arik Yoz, is departing the company.
  2. 02His exit follows Teva's presentation of its innovative medicines strategy and 2030 revenue targets.
  3. 03Dr. David Gardiner will temporarily lead R&D operations.
  4. 04Teva is actively searching for a permanent replacement for Yoz.
  5. 05CEO Richard Francis affirmed that Teva's strategic goals remain unchanged.

Dr. David Gardiner will temporarily lead R&D while Teva searches for a permanent replacement. CEO Richard Francis stated that the company's strategy and goals remain unchanged.

Translated and summarized by baba from Calcalist, the latest report. Read Calcalist’s original

The coverage

2 newsrooms on this story

Who covered it

  • LeftNone
  • CentreNone
  • RightNone
  • HarediNone
  • ArabNone
  • Other2

How it broke

See which of the 2 newsrooms broke it, and who waited